When managing diabetes, clinicians rely on laboratory markers to assess glycemic control and guide therapy. The Hemoglobin A1c (HbA1c) test and the fructosamine test both estimate average blood glucose levels, but they reflect different time windows and depend on different protein compartments. Discrepancies between these values are not uncommon, and understanding the underlying causes is essential to avoid misinterpretation and tailor treatment appropriately. This article explores the physiological basis of each test, the factors that drive discordant results, and the clinical strategies for resolving such discrepancies.

Physiological Basis of Hemoglobin A1c

The Hemoglobin A1c test measures the percentage of hemoglobin molecules in red blood cells that have undergone nonenzymatic glycation — the attachment of glucose to the N-terminal valine of the hemoglobin beta chain. Because red blood cells circulate for an average of 120 days, HbA1c reflects integrated glucose exposure over the preceding 2–3 months. Standardized assays report HbA1c as a percentage, which correlates with an estimated average glucose (eAG) in mg/dL or mmol/L. The strong association between HbA1c and diabetic complications, established by the Diabetes Control and Complications Trial (DCCT) and the United Kingdom Prospective Diabetes Study (UKPDS), has made it the cornerstone of long-term glycemic monitoring.

Several factors can alter HbA1c independent of glycemia. Any condition that changes red blood cell lifespan — hemolytic anemia, recent blood transfusion, erythropoietin therapy, or splenectomy — will shift HbA1c lower or higher than expected for actual glucose levels. Hemoglobin variants (e.g., HbS, HbC, HbE, HbF, or thalassemia) can interfere with certain assay methods, leading to spuriously low or high results. The National Glycohemoglobin Standardization Program (NGSP) certifies methods that minimize these interferences, but no assay is perfect. Clinicians should know their laboratory’s specific method and its known vulnerability to variants.

Despite these limitations, HbA1c remains the gold standard because of its standardization and prognostic value. The American Diabetes Association (ADA) recommends individualized targets, with a general goal below 7% for many nonpregnant adults, though tighter or looser goals apply based on age, comorbidities, and hypoglycemia risk.

Physiological Basis of Fructosamine

The fructosamine test measures the total concentration of glycated serum proteins — principally albumin, which constitutes about 80% of the glycated fraction. Because the half-life of albumin is approximately 14–20 days, fructosamine reflects average glucose over the preceding 2–3 weeks. Results are reported in μmol/L, often normalized to total protein or albumin to improve accuracy. Fructosamine is particularly useful when HbA1c is unreliable, such as in hemolytic anemias, hemoglobinopathies, or chronic kidney disease undergoing dialysis. It also detects rapid glycemic changes more quickly, making it valuable when therapy is adjusted and early assessment is needed.

However, fructosamine has its own limitations. Conditions that alter serum albumin concentrations — liver disease, nephrotic syndrome, malnutrition, or inflammatory states — can affect the test. Low albumin reduces the protein available for glycation, lowering fructosamine even if glucose is elevated. High albumin (e.g., in multiple myeloma or dehydration) can falsely elevate fructosamine. Laboratories that report fructosamine adjusted for albumin partially address this, but not all do. Additionally, fructosamine is less standardized than HbA1c, and there is no universally accepted target range.

Why A1c and Fructosamine Levels Differ

Discrepancies between HbA1c and fructosamine are defined when one test suggests a different level of glycemic control than the other — for example, high HbA1c with normal fructosamine, or vice versa. Clinically, a difference of more than 15–20% between the estimated average glucose from each test often triggers investigation. The causes can be grouped into several categories.

Red Blood Cell Lifespan and Turnover

Any process that shortens red blood cell survival — hemolysis, recent blood loss, splenomegaly, or hypersplenism — reduces the time available for glucose to glycate hemoglobin, resulting in a falsely low HbA1c. In such cases, fructosamine remains unaffected because it depends on albumin. Conversely, conditions that prolong red cell lifespan, such as iron deficiency anemia, asplenia, or aplastic anemia, can elevate HbA1c. Iron deficiency anemia has been shown to raise HbA1c by 1–2 percentage points in some patients, which normalizes after iron supplementation. This effect is particularly important in populations with high rates of iron deficiency.

Hemoglobin Variants and Anemias

Hemoglobin variants (HbS, HbC, HbE, HbF) and thalassemias interfere with HbA1c assays in method-specific ways. High-performance liquid chromatography (HPLC) may produce abnormal chromatograms that are flagged, but some point-of-care immunoassays do not. Fructosamine is measured by a colorimetric method that does not involve hemoglobin, so it is unaffected. For patients known to carry a variant, the ADA recommends using a fructosamine or glycated albumin test when HbA1c is discordant with clinical presentation. Even in sickle cell trait (HbAS), some assays produce a moderate downward bias. In sickle cell disease (HbSS), the markedly shortened red cell lifespan makes HbA1c essentially uninterpretable.

Serum Protein Abnormalities

Low albumin states — common in nephrotic syndrome, liver cirrhosis, severe malnutrition, or chronic inflammation — reduce substrate for glycation and lower fructosamine. A patient with poorly controlled diabetes and cirrhosis may have a misleadingly low fructosamine. High albumin levels (e.g., in multiple myeloma, Hodgkin lymphoma, or dehydration) can falsely elevate fructosamine. Even when adjusted for albumin, the adjustment equations may not account for all confounders. In these cases, HbA1c remains reliable provided no red cell issues exist.

Rapid Glycemic Changes

Because fructosamine reflects only the past 2–3 weeks, it responds more quickly to recent improvements or deteriorations than HbA1c. If a patient drastically changes diet or medication — starting a very low-calorie diet, bariatric surgery, or a potent glucose-lowering agent — fructosamine may drop significantly while HbA1c remains elevated from preceding months. This is not a true discrepancy but a time lag. Both tests are accurate within their respective windows, but discordance arises if clinicians expect agreement. Rechecking HbA1c after 3 months typically shows convergence. Similarly, a new diagnosis of diabetes may show normal HbA1c but elevated fructosamine if hyperglycemia is recent.

Medication Influences

Several medications affect red blood cell turnover or protein metabolism. Dapsone, ribavirin, and high-dose salicylates cause hemolysis and can artifactually lower HbA1c. Antiretroviral therapy (e.g., zidovudine) and some chemotherapeutic agents have been associated with altered HbA1c readings. Fructosamine may be affected by drugs that change protein synthesis or degradation. Corticosteroids increase albumin synthesis, potentially elevating fructosamine. Anabolic steroids, growth hormone, and thyroid hormone also influence protein turnover. A careful medication history is essential when interpreting a discrepancy. Additionally, certain drugs like high-dose vitamin C have been reported to interfere with fructosamine assays through redox reactions.

Pregnancy and Gestational Diabetes

In pregnancy, hemodilution lowers albumin, potentially reducing fructosamine. Accelerated erythropoiesis and shortened red cell survival can lower HbA1c as well, but the net effect varies. For gestational diabetes, fructosamine is sometimes used as an adjunct to self-monitoring of blood glucose, but its utility is debated due to rapid physiological changes and the lack of validated trimester-specific reference ranges. HbA1c also underestimates glycemia in pregnancy because of increased red cell turnover. Many experts recommend using continuous glucose monitoring (CGM) as the gold standard for pregnancy.

Chronic Kidney Disease (CKD)

Chronic kidney disease introduces multiple confounding variables. Reduced erythropoietin production and shortened red cell survival lower HbA1c, while anemia of chronic disease and iron deficiency can have opposing effects. Hypoalbuminemia from proteinuria lowers fructosamine. In CKD stages 4–5, neither test is ideal. Some studies show that fructosamine correlates better with average glucose than HbA1c in dialysis patients, but others find poor correlation. Glycated albumin has been proposed as a superior alternative because it is less affected by hemoglobin and albumin abnormalities. For patients with CKD, the ADA suggests using alternating markers or CGM when discordance is suspected.

Clinical Significance and Decision Making

When a discrepancy is identified, the clinician should first confirm that both tests were performed correctly using validated methods. Next, a thorough review of hematologic status, liver and renal function, medications, and recent glycemic trends should be undertaken. The goal is to determine which test — if either — accurately reflects the patient’s true average glucose.

In many cases, the discrepancy is explainable and does not require abandoning either test. For instance, a patient with sickle cell trait may have an artificially low HbA1c; fructosamine should be relied upon for short-term monitoring. Conversely, a patient with cirrhosis and low albumin may have a falsely low fructosamine; HbA1c, if free from red cell interference, becomes the more trustworthy marker. However, when both tests are potentially confounded (e.g., CKD with anemia and hypoalbuminemia), alternative approaches such as CGM or glycated albumin are needed.

Case reports illustrate these principles. A case described in the NIH case library involved a patient with hemoglobin C trait whose HbA1c by immunoassay was 6.5% but whose fructosamine corresponded to a much higher average glucose; switching to HPLC revealed the correct value. Another example from the ADA clinical practice journal highlighted the use of fructosamine in a patient with iron-deficiency anemia whose HbA1c dropped after iron supplementation, unmasking previously underestimated glycemia. A third case in the literature demonstrated that a patient with CKD on hemodialysis had a HbA1c of 5.8% and a fructosamine of 420 μmol/L, consistent with hyperglycemia; CGM confirmed average glucose of 180 mg/dL, indicating that fructosamine was more accurate.

Emerging Role of Glycated Albumin

Glycated albumin (GA) is gaining traction as an alternative marker that offers the same 2–3 week window as fructosamine but is less affected by albumin concentration because it directly measures the percentage of glycated albumin. GA is expressed as a percentage of total albumin and is not influenced by changes in albumin concentration. In patients with CKD, GA correlates better with CGM metrics than HbA1c. In pregnancy, GA may have more stable reference ranges than fructosamine. However, GA is not yet as widely available or standardized as HbA1c. The FDA has approved GA for commercial use, and several labs now offer it. For complex patients, GA may be superior to both HbA1c and fructosamine.

Practical Recommendations for Clinicians

To minimize confusion from A1c-fructosamine discrepancies, consider the following approaches:

  • Obtain a baseline: When initiating diabetes therapy or when a patient has a known confounder, measure both HbA1c and fructosamine to establish the individual relationship. Subsequent changes can then be interpreted relative to that baseline.
  • Use HbA1c as the primary monitor for most patients, and reserve fructosamine for conditions that render HbA1c unreliable: anemia, hemoglobinopathy, kidney disease, recent transfusion, or rapid glycemic changes.
  • When discrepancies arise that cannot be explained by physiological factors, consider an alternative method for HbA1c (e.g., switching from immunoassay to HPLC) or ordering glycated albumin. CGM can provide definitive confirmation.
  • Document the discrepancy in the medical record along with the presumed cause. This prevents future misinterpretation and unnecessary treatment changes.
  • Educate patients about why different tests are used and what each tells us about glucose control. Patient understanding improves adherence and trust.

Example Scenario: A 55-year-old woman with type 2 diabetes, stage 4 CKD (eGFR 25 mL/min), and mild anemia (Hb 11.0 g/dL) has an HbA1c of 6.2% and a fructosamine of 380 μmol/L (normal < 286). Her self-monitored blood glucose shows average of 170 mg/dL. The discordance is explained by shortened red cell lifespan (low HbA1c) versus near-normal albumin (28 g/dL) that still allows glycation. In this case, fructosamine and CGM are more reliable. The endocrinologist orders glycated albumin (GA 28%, normal 11–16%) and adjusts therapy accordingly.

For more detailed guidance, the ADA Standards of Care provides updated recommendations on using alternative markers. The NGSP website lists certified HbA1c methods and known interferences. A comprehensive review of fructosamine and glycated albumin by the Journal of Diabetes Science and Technology summarizes their clinical utility.

Conclusion

Both Hemoglobin A1c and fructosamine are valuable markers of glycemic control, but they serve complementary roles due to different biokinetics and reliance on distinct biological compartments. Discrepancies between them are not rare and are most often explained by alterations in red blood cell turnover, hemoglobin variants, serum protein abnormalities, rapid glycemic changes, or medication effects. Rather than dismissing one test as wrong, clinicians should view discordance as a diagnostic clue — a signal that prompts investigation into the patient’s underlying physiology. By synthesizing information from both tests with the patient’s clinical story, healthcare providers can achieve a more accurate and nuanced picture of glycemic status. In complex cases, glycated albumin or continuous glucose monitoring should be employed to resolve uncertainty and optimize diabetes management.